908 Devices Third Quarter 2026 Financial Results Conference Call - 908 DEVICES INC

Explicit Guidance:

• FY2026 Revenue: Raised low-end; full-year range of $68.5M to $70M (22–25% YoY growth).
• FY2026 Revenue Mix: Handheld product and service revenue expected to grow 24–27% YoY ($65.5M–$67M); OEM and funded partnerships expected at ~$3M.
• FY2026 Profitability: Adjusted gross margins expected in the mid-to-high 50% range; Adjusted EBITDA loss expected to be in the mid-single-digit millions (approx. 1/3 reduction from FY2025), aiming toward break-even.
• FY2026 Q4 Revenue: Projected ~20% YoY growth at the midpoint; reaching the upper guidance end requires ~24% Q4 growth.
• FY2027 Revenue Outlook: Not explicitly quantified, but management expects sustained growth driven by NearLab, Next-Gen MX908, and AVCAD. Specific targets include NearLab device placements growing to 5M+ units by 2027.

Business-Segment Outlook:

• FTIR Products: Core growth driver; expecting continued strength in international markets (currently 40% of revenue) and U.S. state/local sectors.
• Mass Spec (MX908): Next-generation MX908 expected to be a meaningful growth driver in 2027, targeting early access shipments in Q4 2026 for commercial orders in 2027. Expected to drive upgrades within an installed base of 3,000+ current devices.
• NearLab: Pipeline accelerating; 1M+ cumulative scans achieved in Q3 (1 scan/minute average, +74% YoY). Sales funnel includes new U.S. state/local agencies and international law enforcement. Expectation to transition from ~3M units in 2026 to 5M+ units in 2027.
• Viper & Explorer: Viper on track to ship >100 units in FY2026; early orders from U.S. transportation agencies signal "land and expand" potential.
• OEM & Funded Partnerships: AVCAD (Chemical Agent Verification) program testing ongoing; potential for Commercial Off-The-Shelf (COTS) orders in 2027, which would yield mid-to-high 50% margins (vs. 30–40% for OEM components).
• Recurring Revenue: Currently 27% of revenue; long-term goal is 30–40% driven by connected services and subscriptions.

Market and Competitive Outlook:

• Threat Landscape: Accelerating emergence of synthetic opioids (e.g., cyclorphine) and A-series nerve agents requires programmable, mass spectrometry-based detection; fixed methods are insufficient.
• Demand Trends: Global defense budgets expanding; customers accelerating modernization of detection capabilities.
• Pricing & Margins: Expectation to ascribe higher value to software/solution bundles (Team Leader + MX908) versus standalone hardware.
• Competitive Position: NearLab and MX908 positioned to win share in "next generation" aerosol and vapor detection cycles; "Team Leader" platform aims to unify fleet management across the portfolio.

Macro / Industry Outlook:

• Regulation: Tightening controls on synthetic compounds (e.g., synthetic kratom) driving demand for rapid field identification.
• Funding Environment: State and local funding sources (UASI, AFG, COPS, HIDA) insulated from federal budget timelines; $1B+ in grants refreshed in mid-2026 with multi-year terms.
• FX: Not explicitly quantified, but international channel investments made in FY2026 to support global growth.

Strategic Initiatives:

• Next-Gen MX908 Launch: Pilot manufacturing underway in Danbury, CT; early access deliveries Q4 2026; full commercial launch targeted for 2027. Features: smaller, lighter, simplified operation, enhanced connected services.
• Team Leader Platform: Expanding fleet management software from FTIR to Next-Gen MX908 and NearLab; monetization via bundled support/service packages.
• AVCAD Program: MX908 devices delivered for analytical testing/evaluation with the U.S. Army; positioned for potential COTS procurement in 2027 under DOD procurement reform.
• Capacity: Manufacturing footprint at Danbury, CT; scaling pilot production to meet early access and beta demand from Europe, Middle East, and Latin America.

Risks and Headwinds to Outlook:

• Funding Dependency: Q4 performance and upper guidance range depend on securing funding and closure timing for key enterprise opportunities.
• Order Concentration: Q3 revenue skewed toward two customers (including a ~$6M APAC order); future quarters require execution across a broader customer base to achieve upper guidance.
• Program Uncertainty: AVCAD revenue is excluded from guidance pending a final decision on the commercial COTS path vs. other procurement options.
• Margin Mix: International product revenues currently exert downward pressure on adjusted gross margins; potential for margin volatility based on mix shifts.

Management Tone on the Future:

• Confidence Level: High confidence in "durability and momentum" of the platform; characterized the quarter as "strong" and "record-breaking."
• Guidance Changes: Raised the low end of FY2026 revenue guidance; maintained full-year EBITDA loss trajectory while emphasizing progress toward break-even.
• Hedges: Qualifiers regarding "material risks and uncertainties" standard for forward-looking statements; caveats on timing for major grants and enterprise contract closures.

Miscellaneous:

• Installed Base: Reached 4,400 devices in the field; ~3,000 are MX908 units.
• Cash Position: Ended Q3 2026 with $99.1M in cash equivalents and marketable securities; zero debt.
• R&D Focus: Significant allocation toward connected services and AI model training (NearLab) to differentiate value proposition against fixed field methods.